SITUATION A leading global pharmaceutical company initiated a clinical trial for a new asthma compound, leveraging standardized, centralized spirometry. During the study, there were large discrepancies in spirometry results produced by investigative sites from subjects’ baseline inclusion measurements when compared to later measurements under treatment. SOLUTION A new study was designed leveraging ERT Respiratory solutions with a more intense statistical outcome sought. To identify and proactively correct any site data quality issues that could impact the second study’s outcome, ERT Enhanced Business Intelligence for Respiratory Trials was also implemented. Based on the study’s primary endpoint, an enhanced report was designed to monitor and manage site performance and subject ou

Join for free to read